Home > Publications database > What is established in the treatment of diffuse large B-cell lymphoma? [Was ist gesichert in der Therapie des diffusen großzelligen B-Zell-Lymphoms?] > print

001     305508
005     20251126144913.0
024 7 _ |a 10.1007/s00108-025-01999-x
|2 doi
024 7 _ |a pmid:41125821
|2 pmid
024 7 _ |a 2731-7080
|2 ISSN
024 7 _ |a 0020-9554
|2 ISSN
024 7 _ |a 1432-1289
|2 ISSN
024 7 _ |a 2731-7099
|2 ISSN
037 _ _ |a DKFZ-2025-02192
041 _ _ |a German
082 _ _ |a 610
100 1 _ |a Alig, Stefan K
|0 P:(DE-HGF)0
|b 0
245 _ _ |a What is established in the treatment of diffuse large B-cell lymphoma? [Was ist gesichert in der Therapie des diffusen großzelligen B-Zell-Lymphoms?]
260 _ _ |a Berlin
|c 2025
|b Springer Medizin
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1764164921_3813576
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2025 Dec;66(12):1258-1266
520 _ _ |a Diffuse large B‑cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma, with a median age at diagnosis of 71 years, predominantly affecting older adults. Risk factors include immunodeficiency, autoimmune disorders, viral infections, and certain environmental exposures, although most cases lack a clear predisposition. Diagnosis is based on lymph node excision, histopathological and molecular analysis, and positron emission tomography-computed tomography (PET-CT) staging. First-line standard therapy is R‑CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), de-escalated to four cycles for young, low-risk patients (FLYER trial). For patients with International Prognostic Index (IPI) ≥ 2, the POLARIX trial showed superior progression-free survival with polatuzumab vedotin-R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) over R‑CHOP. Older patients are generally treated with dose-reduced R‑mini-CHOP or alternatives. In relapsed/refractory disease, chimeric antigen receptor (CAR) T‑cell therapy with axicabtagene ciloleucel or lisocabtagene maraleucel has replaced high-dose chemotherapy with autologous stem cell transplantation for refractory or early relapses, including transplant-ineligible patients. Additional antibody-based therapies-such as polatuzumab-bendamustine-rituximab, tafasitamab-lenalidomide, loncastuximab, and bispecific antibodies (glofitamab, epcoritamab, odronextamab)-expand treatment options, some achieving durable remissions. Glofitamab plus gemcitabine-oxaliplatin is a new standard for first relapse when CAR T‑cell therapy is not feasible or as bridging before CAR T. Future directions include earlier integration of immunotherapies, personalized strategies guided by genetic subgroups, and broader use of liquid biopsy for subtyping, minimal residual disease detection, and treatment guidance.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Antibodies, bispecific
|2 Other
650 _ 7 |a CAR T‑cell therapy
|2 Other
650 _ 7 |a CHOP protocol
|2 Other
650 _ 7 |a Lymphoma, non-Hodgkin
|2 Other
650 _ 7 |a Rituximab
|2 Other
700 1 _ |a Reinhardt, Annekathrin
|0 P:(DE-He78)856d5c1d0205a79190ed88218ffaf9b2
|b 1
700 1 _ |a von Tresckow, Bastian
|0 P:(DE-HGF)0
|b 2
773 _ _ |a 10.1007/s00108-025-01999-x
|0 PERI:(DE-600)3124793-3
|n 12
|p 1258-1266
|t Die Innere Medizin
|v 66
|y 2025
|x 2731-7080
909 C O |p VDB
|o oai:inrepo02.dkfz.de:305508
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)856d5c1d0205a79190ed88218ffaf9b2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2025
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2025-01-07
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2025-01-07
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-01-07
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-07
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b INNERE MED : 2022
|d 2025-01-07
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2025-01-07
920 1 _ |0 I:(DE-He78)ED01-20160331
|k ED01
|l DKTK Koordinierungsstelle Essen/Düsseldorf
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)ED01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21